Decitabine

Decitabine
Clinical data
Trade namesDacogen, Demylocan
Other names5-aza-2'-deoxycytidine
AHFS/Drugs.comMonograph
MedlinePlusa608009
License data
Routes of
administration		Intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding<1%
Elimination half-life30 minutes
Identifiers
  • 4-Amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.017.355 Edit this at Wikidata
Chemical and physical data
FormulaC8H12N4O4
Molar mass228.208 g·mol−1
3D model (JSmol)
  • O=C1/N=C(\N=C/N1[C@@H]2O[C@@H]([C@@H](O)C2)CO)N
  • InChI=1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1 checkY
  • Key:XAUDJQYHKZQPEU-KVQBGUIXSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Decitabine (i.e., 5-aza-2′-deoxycytidine), sold under the brand name Dacogen among others, acts as a nucleic acid synthesis inhibitor.[4] It is a medication for the treatment of myelodysplastic syndromes, a class of conditions where certain blood cells are dysfunctional, and for acute myeloid leukemia (AML).[5] Chemically, it is a cytidine analog.

  1. ^ "Summary Basis of Decision (SBD) for Dacogen". Health Canada. 23 October 2014. Retrieved 29 May 2022.
  2. ^ "Summary Basis of Decision (SBD) for Demylocan". Health Canada. 23 October 2014. Retrieved 29 May 2022.
  3. ^ "Dacogen EPAR". European Medicines Agency (EMA). 8 June 2006. Retrieved 4 June 2024.
  4. ^ "Decitabine". National Center for Biotechnology Information. Retrieved September 24, 2016.
  5. ^ "EC Approves Marketing Authorization Of DACOGEN For Acute Myeloid Leukemia". 2012-09-28. Retrieved 28 September 2012.